Aim: To study and learn the role of anti-pneumococcal antibody and the development of vaccines for COVID 19. Materials and Methods: Review of Literature by collecting and retrieving information from a minimum of articles. Discussion: The antibody-polysaccharide antigens, such as the pneumococcal vaccine. Polysaccharide pneumococcal vaccines have evolved over the past 20 years, using both unconjugated polysaccharides and polysaccharides conjugated to toxins to elicit a protective immune response in groups at risk for pneumococcal infection. Current CDC immunization guidelines for these vaccines have reduced the rates of pneumococcal infections within immunized communities. Vaccines against pneumonia, such as a pneumococcal vaccine, do protect against the COVID 19. Conclusion: We acknowledge that the development of pneumococcal vaccine may not protect against the coronavirus. More affordable and accessible vaccines for pneumonia are needed to protect from vaccines to kill the coronavirus in one shot. As the virus is new and different as it needs its vaccine.